Major Shareholder Atlas Venture Files Intent to Sell $6.7M in Kymera Therapeutics Stock
Summary
A major institutional shareholder, Atlas Venture Opportunity Fund I, LP, filed a Form 144 to sell $6.72 million in Kymera Therapeutics stock, continuing a pattern of significant share distribution.
Key Events
-
Intent to Sell Shares
Atlas Venture Opportunity Fund I, LP, a significant shareholder, filed a Form 144 to sell 67,329 shares of common stock, valued at approximately $6.72 million.
-
Ongoing Share Distribution
This filing is part of a broader pattern of share distribution by Atlas Venture entities, which have sold over $70 million in Kymera Therapeutics stock over the last three months.
Analysis
Atlas Venture Opportunity Fund I, LP, a significant institutional shareholder, has filed a Form 144 indicating its intent to sell approximately $6.72 million worth of Kymera Therapeutics common stock. This filing is part of an ongoing pattern of distribution by Atlas Venture entities, which have collectively sold over $70 million in shares over the past three months. This continuous selling by a major investor can create sustained selling pressure on the stock.
At the time of this filing, KYMR was trading at $115.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.6B. The 52-week trading range was $36.65 to $130.05. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.